Most of what makes this study worth reading is a check the authors ran on themselves. Finding no difference has two explanations — there is not one, or the study could not have seen one — and almost nothing published bothers to separate them.
What was compared
Adults with overweight or obesity and type 2 diabetes starting tirzepatide or injectable semaglutide, drawn from a global research network and matched on baseline characteristics. [1] The outcome was time to a first major adverse liver outcome: cirrhosis, a decompensating event, or liver cancer.
This is a target trial emulation — an observational comparison built to behave like a trial, with eligibility and follow-up rules fixed in advance. It still does not randomize anyone.
The result
Over a median of roughly 17 months, incidence ran at 4.05 per 1000 person-years on tirzepatide and 4.04 on semaglutide — a hazard ratio of 1.04, 95% CI 0.88 to 1.23.
Among patients with fatty liver the rates were 9.97 and 10.03 per 1000 person-years, hazard ratio 1.03, 95% CI 0.75 to 1.42. An as-treated analysis gave 0.98, 95% CI 0.80 to 1.21. Three ways of asking, three intervals sitting squarely across one.
More weight, same liver
Tirzepatide achieved about 1.1 kg/m2 more reduction in body mass index, p < 0.001. It did not produce fewer liver events.
Over seventeen months that is not a contradiction — it takes years for cirrhosis or liver cancer to arrive, and a difference in weight would have to work through a long causal chain to show up in those counts. It does sit alongside the study where surgery lost more weight and improved liver stiffness no further, and the two together make the weight-to-liver link look less automatic than it is usually described.
What the window can carry
Seventeen months is short for these endpoints and the authors say so, describing their conclusion as short- to medium-term. What the study supports is that neither drug is worse than the other on liver outcomes over that stretch.
That is genuinely useful for anyone weighing the two, and it is not the same as either drug having been shown to prevent liver disease — a claim that needs the trial evidence in that population and, for the approval that exists, a fibrosis stage somebody has actually measured.